GK01 Injection

DRUG6 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Beijing Geekgene Technology Co., LTD

Conditions

Advanced Lung CancerAdvanced Solid TumorsSolid Tumors

Early Phase 1

A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.

RecruitingNCT07414316

Beijing Geekgene Technology Co., LTDAdvanced Solid Tumors

Start: 2026-02-13End: 2028-02-12Target: 10Updated: 2026-02-17

A Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.

Not yet recruitingNCT07412665

Beijing Geekgene Technology Co., LTDAdvanced Solid Tumors

Start: 2026-06-01End: 2028-03-31Target: 10Updated: 2026-06-25

A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer

Not yet recruitingNCT07673419

Beijing Geekgene Technology Co., LTDAdvanced Lung Cancer

Start: 2026-07-01End: 2028-07-01Target: 10Updated: 2026-06-29

Phase 1

A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor

RecruitingNCT06954558

Tianjin Medical University Cancer Institute and HospitalAdvanced Solid Tumors

Start: 2025-03-18End: 2028-07-18Target: 15Updated: 2025-05-01

A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors

RecruitingNCT07351903

Tianjin Medical University Cancer Institute and HospitalSolid Tumors

Start: 2025-10-16End: 2029-02-14Target: 15Updated: 2026-01-20

A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors

Not yet recruitingNCT07482319

Beijing Geekgene Technology Co., LTDAdvanced Solid Tumors

Start: 2026-04-01End: 2028-04-01Target: 15Updated: 2026-03-23

Related Papers

GK01 stemness-enriched tumor-reactive T-cell therapy plus IL-2 in advanced solid tumors: ORR and clonal persistence results in a first-in-human phase I study (GUARDIAN-01).

Journal of Clinical Oncology2026-05-27